Leerink Partnrs Issues Pessimistic Forecast for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a report issued on Wednesday, October 23rd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $5.97 per share for the quarter, down from their previous estimate of $6.04. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $21.72 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q1 2025 earnings at $5.59 EPS, Q2 2025 earnings at $5.77 EPS, Q3 2025 earnings at $5.79 EPS, Q4 2025 earnings at $6.67 EPS, FY2025 earnings at $23.81 EPS and FY2026 earnings at $26.49 EPS.

A number of other research analysts have also commented on TMO. Robert W. Baird cut their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday. Evercore ISI decreased their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $554.38 on Friday. The stock has a market capitalization of $211.77 billion, a PE ratio of 34.39, a P/E/G ratio of 3.75 and a beta of 0.77. The stock has a 50-day simple moving average of $606.12 and a 200 day simple moving average of $584.21. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific has a twelve month low of $420.21 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same period last year, the business posted $5.69 EPS. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TMO. Brookstone Capital Management increased its stake in shares of Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after acquiring an additional 3,142 shares during the last quarter. BDF Gestion bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth about $6,368,000. Aviance Capital Partners LLC grew its position in shares of Thermo Fisher Scientific by 20.9% in the 1st quarter. Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock valued at $7,581,000 after purchasing an additional 2,251 shares during the period. Lord Abbett & CO. LLC raised its holdings in Thermo Fisher Scientific by 1.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock worth $45,478,000 after buying an additional 1,480 shares during the period. Finally, Advisors Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 5.8% in the first quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock valued at $64,613,000 after buying an additional 6,089 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 6,300 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total value of $3,793,167.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,548,375.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 6,300 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 29th. The stock was sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,548,375.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.